interest are found at the end of this article.

Gastric cancer is the fourth most common cancer in men and the fifth most common cancer in wom-en worldwide (Jemal et al., 2011). The American Cancer Society (ACS) has estimated there were 22,220 new cases diagnosed in 2014, with an es-timated 10,990 deaths (Siegel, Ma, Zou, & Jemal, 2014). Despite some advances in treatment, gastric can-cer continues to be associated with poor outcomes. Approximately two-thirds of pa-tients diagnosed with gastric cancer have locally advanced or metastatic disease, with a median survival of around 10 months (Chau et al., 2004). Chemotherapy is the primary modal-ity for management of advanced and metastatic gastric cancers and has been shown to improve quality of life and prolong survival (Wagner et al., 2006). The standard of care for treat-ment of advanced disease is poorly defined, with no preferred first- or second-line regimens. Category 1 recommendations for first-line therapy for locally advanced and metastatic disease include a two-drug regimen of cisplatin combined with a fluoropyrimidine (fluoroura-cil or capecitabine) or cisplatin and a fluoropyrimidine combined with a third agent, which is typically epi-rubicin or docetaxel. Two-drug regi-mens are generally preferred, since they are associated with less toxic